Understanding why some blood infections with Candida and MRSA are persistent
Official title: Human Immunomics & Trained Immunity in Persistent Candidemia
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11351005 · Data updated 2026-11-12
Researchers are studying why certain fungal and bacterial infections stay stubborn in hospitalized patients and how the body’s immune system responds over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | August 10, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $531,722 |
| NIH project number | 5U19AI172713-04 |
| Project ID | NIH-11351005 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with hematologic disseminated candidiasis or invasive MRSA infections who are receiving standard antifungal or anti-infective therapy.
✕Less likely to help
Patients without these infections or those not undergoing relevant sampling/immune profiling may not benefit from this study.
What this research studies
This project will follow patients with hematologic disseminated candidiasis and MRSA infections using advanced immune profiling and multi-omics to map how innate and adaptive immunity changes during infection and treatment. By analyzing patient blood samples, infection-derived materials, and immune responses, the team aims to build a detailed picture of the immune pathways involved. The study will integrate statistical and computational modeling to predict how immune networks behave and respond to therapies. The goal is to uncover targets that could improve survival and guide more effective treatments for these serious infections.
Why it matters
Potential benefit: If successful, the research could lead to more precise immune-targeted therapies and better clinical strategies to reduce mortality from HDC and MRSA infections.
How similar studies have gone: Similar multi-omics approaches have yielded deeper immune insights in infectious diseases, supporting the potential value of this strategy.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Reed, Elaine F — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Reed, Elaine F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.